236 related articles for article (PubMed ID: 17415548)
1. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.
Fyfe MC; White JR; Taylor A; Chatfield R; Wargent E; Printz RL; Sulpice T; McCormack JG; Procter MJ; Reynet C; Widdowson PS; Wong-Kai-In P
Diabetologia; 2007 Jun; 50(6):1277-87. PubMed ID: 17415548
[TBL] [Abstract][Full Text] [Related]
2. SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.
Bertram LS; Black D; Briner PH; Chatfield R; Cooke A; Fyfe MC; Murray PJ; Naud F; Nawano M; Procter MJ; Rakipovski G; Rasamison CM; Reynet C; Schofield KL; Shah VK; Spindler F; Taylor A; Turton R; Williams GM; Wong-Kai-In P; Yasuda K
J Med Chem; 2008 Jul; 51(14):4340-5. PubMed ID: 18588279
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
[TBL] [Abstract][Full Text] [Related]
4. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.
De Ceuninck F; Kargar C; Ilic C; Caliez A; Rolin JO; Umbdenstock T; Vinson C; Combettes M; de Fanti B; Harley E; Sadlo M; Lefèvre AL; Broux O; Wierzbicki M; Fourquez JM; Perron-Sierra F; Kotschy A; Ktorza A
Br J Pharmacol; 2013 Jan; 168(2):339-53. PubMed ID: 22925001
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
[TBL] [Abstract][Full Text] [Related]
6. S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.
De Ceuninck F; Kargar C; Charton Y; Goldstein S; Perron-Sierra F; Ilic C; Caliez A; Rolin JO; Sadlo M; Harley E; Vinson C; Ktorza A
Br J Pharmacol; 2013 Jul; 169(5):999-1010. PubMed ID: 23488540
[TBL] [Abstract][Full Text] [Related]
7. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
Baker DJ; Wilkinson GP; Atkinson AM; Jones HB; Coghlan M; Charles AD; Leighton B
Br J Pharmacol; 2014 Apr; 171(7):1642-54. PubMed ID: 24772484
[TBL] [Abstract][Full Text] [Related]
8. Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat.
Futamura M; Yao J; Li X; Bergeron R; Tran JL; Zycband E; Woods J; Zhu Y; Shao Q; Maruki-Uchida H; Goto-Shimazaki H; Langdon RB; Erion MD; Eiki J; Zhou YP
Diabetologia; 2012 Apr; 55(4):1071-80. PubMed ID: 22234649
[TBL] [Abstract][Full Text] [Related]
9. Allosteric activators of glucokinase: potential role in diabetes therapy.
Grimsby J; Sarabu R; Corbett WL; Haynes NE; Bizzarro FT; Coffey JW; Guertin KR; Hilliard DW; Kester RF; Mahaney PE; Marcus L; Qi L; Spence CL; Tengi J; Magnuson MA; Chu CA; Dvorozniak MT; Matschinsky FM; Grippo JF
Science; 2003 Jul; 301(5631):370-3. PubMed ID: 12869762
[TBL] [Abstract][Full Text] [Related]
10. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection.
Lei L; Liu S; Li Y; Song H; He L; Liu Q; Sun S; Li Y; Feng Z; Shen Z
Eur J Pharmacol; 2018 May; 826():17-23. PubMed ID: 29477658
[TBL] [Abstract][Full Text] [Related]
11. TMG-123, a novel glucokinase activator, exerts durable effects on hyperglycemia without increasing triglyceride in diabetic animal models.
Tsumura Y; Tsushima Y; Tamura A; Hasebe M; Kanou M; Kato H; Kobayashi T
PLoS One; 2017; 12(2):e0172252. PubMed ID: 28207836
[TBL] [Abstract][Full Text] [Related]
12. Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes.
Al-Oanzi ZH; Fountana S; Moonira T; Tudhope SJ; Petrie JL; Alshawi A; Patman G; Arden C; Reeves HL; Agius L
Diabetes Obes Metab; 2017 Aug; 19(8):1078-1087. PubMed ID: 28206714
[TBL] [Abstract][Full Text] [Related]
13. Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
Deshpande AM; Bhuniya D; De S; Dave B; Vyavahare VP; Kurhade SH; Kandalkar SR; Naik KP; Kobal BS; Kaduskar RD; Basu S; Jain V; Patil P; Chaturvedi Joshi S; Bhat G; Raje AA; Reddy S; Gundu J; Madgula V; Tambe S; Shitole P; Umrani D; Chugh A; Palle VP; Mookhtiar KA
Eur J Med Chem; 2017 Jun; 133():268-286. PubMed ID: 28390958
[TBL] [Abstract][Full Text] [Related]
14. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
[TBL] [Abstract][Full Text] [Related]
15. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Patel V; Patel K; Bahekar R; Jain M
Eur J Pharmacol; 2013 Aug; 714(1-3):188-92. PubMed ID: 23810686
[TBL] [Abstract][Full Text] [Related]
16. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator.
Johnson D; Shepherd RM; Gill D; Gorman T; Smith DM; Dunne MJ
Diabetes; 2007 Jun; 56(6):1694-702. PubMed ID: 17360975
[TBL] [Abstract][Full Text] [Related]
17. Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells.
Wei P; Shi M; Barnum S; Cho H; Carlson T; Fraser JD
Diabetologia; 2009 Oct; 52(10):2142-50. PubMed ID: 19641898
[TBL] [Abstract][Full Text] [Related]
18. Identification of a new class of glucokinase activators through structure-based design.
Hinklin RJ; Boyd SA; Chicarelli MJ; Condroski KR; DeWolf WE; Lee PA; Lee W; Singh A; Thomas L; Voegtli WC; Williams L; Aicher TD
J Med Chem; 2013 Oct; 56(19):7669-78. PubMed ID: 24015910
[TBL] [Abstract][Full Text] [Related]
19. A novel glucokinase activator modulates pancreatic islet and hepatocyte function.
Efanov AM; Barrett DG; Brenner MB; Briggs SL; Delaunois A; Durbin JD; Giese U; Guo H; Radloff M; Gil GS; Sewing S; Wang Y; Weichert A; Zaliani A; Gromada J
Endocrinology; 2005 Sep; 146(9):3696-701. PubMed ID: 15919746
[TBL] [Abstract][Full Text] [Related]
20. Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats.
Coope GJ; Atkinson AM; Allott C; McKerrecher D; Johnstone C; Pike KG; Holme PC; Vertigan H; Gill D; Coghlan MP; Leighton B
Br J Pharmacol; 2006 Oct; 149(3):328-35. PubMed ID: 16921397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
